Uterine Fibroids: From Pathogenic Signalling and Molecular Classification to Precision Diagnosis and the Evolving Landscape of Minimally Invasive Management

Abstract

Uterine fibroids, or uterine leiomyomas, are the most common non-cancerous tumours, affecting women in their reproductive years. Their occurrence shows considerable variation, with prevalence estimates ranging from 4.5% to almost 70%, and notably higher rates seen in African American women. While many women with fibroids do not develop symptoms, a substantial proportion experience significant clinical issues, including heavy menstrual bleeding, persistent pelvic pain, pressure sensations, subfertility, and adverse pregnancy outcomes. The formation of these tumors is closely linked to hormonal influences and genetic alterations—especially mutations in the MED12 gene—as well as excessive extracellular matrix deposition driven by profibrotic pathways. Diagnosis relies on pelvic examination supported by imaging, with ultrasonography and magnetic resonance imaging (MRI) serving as principal tools. The FIGO classification system further assists clinicians in accurately identifying fibroid types based on anatomical location. Management is individualized, considering symptom severity, reproductive goals, and the patient’s overall clinical profile. Therapeutic options range from medical treatments such as NSAIDs, tranexamic acid, hormonal agents, progestins, and GnRH analogues, to minimally invasive techniques including uterine artery embolization and MRI-guided focused ultrasound. Surgical procedures like myomectomy and hysterectomy continue to serve as definitive interventions, particularly in complex or recurrent cases. Growing insights into molecular mechanisms and targeted therapeutic pathways are gradually transforming fibroid care toward more precise, minimally invasive, and fertility-conserving treatment strategies.

Keywords

Introduction

Myomas or uterine leiomyomas are other names for uterine fibroids (UFs), which are the most prevalent benign tumors in women who are fertile. These non-cancerous masses are rich in extracellular matrix and come from the smooth muscle of the uterine wall, or myometrium. Prevalence rates range greatly, from 4.5% to a startling 68.6%, frequently spiking as women get closer to 50.Even though fibroids are frequently asymptomatic, many people's quality of life is greatly reduced by them.[1][2] Heavy and extended menstrual bleeding (HMB), persistent pelvic pain, and bladder or rectum pressure feelings are among the symptoms. Pregnancy and fertility are also at risk. Even though they are benign, symptomatic fibroids are a main reason for big procedures like hysterectomy. More likely to have them due to a combination of environmental, hormonal, The female sex hormones, progesterone and estrogen, are the main causes of the complicated etiology, which results in growth throughout the reproductive years and regression following menopause. Growth is facilitated by a number of growth factors, and genetic predisposition plays a significant role.[3]It is noteworthy that there is a significant racial gap in the prevalence of fibroids, with African American women. It is noteworthy that there is a significant racial gap in the prevalence of fibroids, with African American women more likely to have them due to a combination of environmental, hormonal, and genetic variables.[4]

EPIDEMIOLOGY:

Leiomyomas, often known as uterine fibroids (UFs), are the most prevalent tumors that mostly affect women throughout their reproductive years. Estimates of the lifetime prevalence range from 40% to 89%, which is remarkably high. [1][2]The cumulative incidence at age 50 exhibits a notable racial disparity, according to epidemiological data. Over 80% for Black women and about 70% for White women.

Economic and Clinical Effects

A significant portion of women—roughly 30%—develop serious symptoms that necessitate treatment, despite the fact that many are asymptomatic.

Key symptoms include:

• Heavy or abnormal menstrual bleeding (AUB/HMB), which frequently results in anemia.[7]
• Symptoms of pelvic pressure and mass that are crippling.
• Ache.
• Serious reproductive problems, such as infertility.

As a result, UFs are a significant public health concern in the US, accounting for up to $34 billion in medical expenses annually and being the primary cause of hysterectomy. UFs are still notably understudied in spite of this.[21,25]

ETIOLOGY:

Uterine Leiomyomas (ULs) are mostly caused by two factors:

• hormonal dependency and genetic alterations.
• Drivers of Genetics

The $MED12$ gene mutation on the X chromosome, which is present in around 70% of fibroids, is the most important genetic component. The gene in question controls RNA polymerase II. [10] Genes like $HMGA1$ and $HMGA2$, as well as $COL4A4$ and $COL4A6$, have also been shown to have mutations. Rare mutations, such as those in fumarate hydratase, are linked to hereditary disorders, such as HLRCC (Hereditary Leiomyomatosis and Renal Cell Cancer).

Dependency on Hormones

In comparison to the surrounding normal uterine muscle, ULs are extremely hormonally sensitive tumors that overexpress both progesterone and estrogen receptors[11][18] Estradiol and progesterone, two ovarian steroids, both actively stimulate fibroid growth, most likely by paracrine stimulation of nearby leiomyoma stem cells.

This hormonal dependency is supported by the following clinical evidence:

• The postpartum fibroid size reduction that occurs naturally.
• How well hormone-suppressive medications (such as GnRH analogs) work.
• The fibroids' usual regression following menopause.[34]

RISK FACTOR FOR UTERINE LEIOMYOMAS

Factors related to race and demography (highest risk)

The biggest and most significant risk factor is race/ethnicity. 

Racial Disparity: African American women are the most vulnerable group; by the age of 50, their projected UL incidence is over 80%, which is far greater than that of Caucasian women (70%).[3[[14]

Disease Severity: More severe disease (earlier diagnosis, larger tumors, greater symptoms) is linked to this discrepancy. 

Intervention Rates: As a result, African American women receive surgical procedures at significantly greater rates than Caucasian women. Even after adjusting for other variables, they are 6.8 times more likely to have a myomectomy and 2.4 times more likely to have a hysterectomy.

Age-Related and Hormonal Factors

Ovarian hormone action and UL growth are closely related Age Profile. After menopause, when tumors are smaller and less symptomatic, the incidence usually decreases.[13] It peaks in the early 40s.

Hormone Hypersensitivity: Progesterone (P4) and estrogen (E2) specifically cause hypersensitivity in UL tissue. In reaction to progesterone, which is generally inhibitory, tumors overexpress aromatase and receptors (ER-$\alpha$, PR). Due to extended exposure to hormones, a higher risk is associated with an earlier menarche age.

Vitamin D: Low levels of 25-hydroxyvitamin D in the blood have been linked to a higher risk.

Reproductive and Lifestyle Factors

Body Weight (BMI/Obesity): There is a dose-response link between high BMI and obesity and an increased incidence of UL, with a 6% increase in risk for every unit increase in BMI.

Exercise and Diet: Consuming green vegetables is connected to a decreased incidence, whereas diets heavy in red meat are linked to a higher risk. Another linked factor is not exercising.

Parity: The risk of UL is negatively correlated with parity; a rise in live births is linked to a fall in risk.[19][24]

PATHOPHYSILOGY:

Origin of Cells and Genes

Genomic instability is associated with the genetic alteration of a single myometrial stem cell (MMSC) or immature cell that causes ULs. Up to 70% of UL patients have a mutation in the $MED12$ gene, which controls RNA polymerase II and is the most important molecular abnormality.

Dependency on Hormones

The ovarian hormones progesterone and estradiol are essential for UL growth. In comparison to healthy muscle, UL tissue overexpresses both hormone receptors.[8]]10] Through paracrine stimulation, in which mature cells emit signals that support the growth of nearby undifferentiated cells, these hormones promote tumor proliferation.[12] This hormonal connection is highly supported by clinical results, such as tumor reduction during menopause.

Aberration of Extracellular Matrix (ECM)

The categorization of ULs as fibrotic illnesses is one of their main features. Compared to normal myometrium, the tumors have about 50% more ECM proteins (mostly collagens, fibronectin, and laminins). Profibrotic growth factors, like activin-A and Transforming Growth Factor beta ($TGF-\beta$), are primarily responsible for this excessive buildup. In addition to acting as a reservoir that stabilizes and prolongs the signaling of these growth factors, the resulting stiff, over-deposited extracellular matrix (ECM) actively promotes tumor growth by triggering signaling pathways through a process known as mechanotransduction.[12][22]

LEIOMYOMAS, OR UTERINE FIBROIDS: CHARACTERISTICS AND SIGNS
SYMPTOMATIC UTERINE FIBROIDS AFFECT A WOMAN'S QUALITY OF LIFE AND REPRODUCTIVE HEALTH IN A NUMBER OF IMPORTANT WAYS.

Unexpected Bleeding

Menorrhagia, or excessive menstruation, is the most common and frequently the only symptom. It is defined by an increase in the amount and duration of monthly blood loss.[4][9] Iron-deficiency anemia frequently results from this acute bleeding.

Pressure and Pain

One typical complaint is pelvic pressure or pain. This may show up as dyspareunia (painful sex) or dysmenorrhea (difficult periods).

Diagnosis and Mass Effect

An increased uterine shape is a common outcome of fibroids. When a clinician feels this growth during an examination, they are frequently discovered. [14][15]Menstrual weeks are typically used to determine the size of the uterus caused by fibroids (for example, a uterus larger than 12 weeks may be felt above the pelvis).

Impact on Reproduction

Fibroids can cause problems during pregnancy and have a detrimental effect on fertility. As a result, reproductive issues frequently manifest, especially when women put off getting pregnant for the first time.

Risk of Malignancy

There is very little chance (less than 0.3%) that a benign fibroid may develop into a malignant leiomyosarcoma. The majority of the data points to leiomyosarcomas developing de novo, or from scratch, and being unconnected to benign fibroids that already existed.[27][34]

DIGNOSIS:

Clinical evaluation and imaging methods are used in the diagnosis of uterine fibroids.

Diagnostic Techniques

A pelvic exam could show an enlarged uterus. Because ultrasound is widely available and reasonably priced, it is regarded as the gold standard for initial diagnosis.

While 3D ultrasound helps reconstruct the uterine anatomy, specialized methods such as Saline-Infusion Ultrasonography (SIS) improve the visibility of submucosal fibroids.

An further method for differentiating between intracavitary fibroids and polyps is hysteroscopy, which is frequently carried out without anesthetic. [6][8] It is essential while preparing for a hysteroscopic myomectomy and permits an endometrial biopsy in cases where there is a risk of malignancy.

The most precise information on the number, size, and precise placement of the fibroids in relation to the uterine cavity is provided by magnetic resonance imaging (MRI), which is essential for surgical planning. Like ultrasonography, MRI cannot, however, completely rule out cancer (sarcoma)

Classification and Conclusive Diagnosis

The International Federation of Gynecology and Obstetrics (FIGO) classification is used to categorize fibroids based on their location. [16][20]Given the slight but real danger of an unanticipated malignancy (leiomyosarcoma is rare, estimated at fewer than 1 to 13 per 10,000 procedures), pathological assessment (after surgery) continues to be the criteria standard for conclusive diagnosis, even while imaging directs diagnosis and conservative treatment. Analyzing Symptoms Clinicians must go beyond basic self-reporting in cases of concomitant Abnormal/ Heavy Menstrual Bleeding (AUB/HMB) and particularly ask about anemia symptoms (fatigue, palpitations) and product volume. Women over 45 or those who have risk factors for endometrial cancer or hyperplasia should have an endometrial biopsy.[28]

MANAGEMENT:

Uterine fibroids require a highly customized treatment approach that takes into account the patient's main circumstances and objectives while concentrating on symptoms:

• Future Fertility: The wish to get pregnant in the future.
• Uterine Preservation: The wish to keep the uterus intact.
• Likelihood of Success: The chance that the intended result will be attained.
• Overall, Health: The state of the patient's overall health.

Treatment Objectives and Approach[2]

• The goal of treatment is to make the fibroids smaller.
• Reduce abnormal uterine bleeding caused by fibroids.
• Offer a permanent remedy for the fibroids.

It is typically advised to use a step-up approach, giving medicinal treatments and less invasive interventional radiology techniques priority before proceeding with surgical procedures. Hysterectomy, or the surgical removal of the uterus, continues to be the most popular definitive treatment for symptomatic fibroids worldwide, accounting for around one-third of all hysterectomies, despite advances in uterine-preserving procedures.

1. NSAIDs, or Non-Steroidal Anti-Inflammatory Drugs^[4][6]

Because they are inexpensive and have few adverse effects, NSAIDs are the first-line treatment for AUB and dysmenorrhea (painful periods).

Mechanism: They decrease the synthesis of pro-inflammatory prostaglandins by inhibiting the cyclooxygenase enzyme.

Effectiveness: When compared to a placebo, they are successful in lowering menorrhagia (heavy bleeding) and relieving dysmenorrhea. However, compared to LNG-IUDs, combined hormonal contraceptives, or tranexamic acid, they are less successful in lowering menstrual blood loss.

Common Agents & Usage: Medications such as Ibuprofen (600–1800 mg daily) or Naproxen (550–1100 mg daily) are usually started 1-2 days prior to or at the start of menstruation and continued for the duration of bleeding.

Steer clear of: Individuals with renal disease, active stomach or peptic ulcers, or known hypersensitivity.

2. Tranexamic Acid (TXA)^[32]

TXA is a traditional, widely accessible, and successful non-hormonal treatment for AUB.

Mechanism: It functions as an anti-fibrinolytic drug and is a synthetic derivative of lysine. By blocking the breakdown of fibrin at the plasminogen lysine receptor site, it favors pro-coagulant processes and increases the production of blood clots and decreases menstrual blood flow.

Dosing: For up to five days, two 650 mg tablets are usually taken orally three times a day.

Side effects, including as gastrointestinal (GI) and musculoskeletal complaints, are often uncommon and minor.

Contraindications include color blindness, medication hypersensitivity, active bleeding (apart from menstruation), and a history of intravascular coagulation.

ADVANCED MEDICAL THERAPIES AND HORMONES FOR THE TREATMENT OF FIBROIDS^[8][17]

Hormonal contraceptives that are combined (CHCs)

For fibroid-related abnormal uterine bleeding (AUB), combined hormonal contraceptives (CHCs), which come in pill, patch, or ring form, are a popular choice. They mostly work by thinning the endometrium, the lining of the uterus, which decreases menstrual flow. Although CHCs raise hemoglobin, improve AUB, and improve quality of life, they are typically less successful than progestin-releasing IUDs at stopping bleeding. Because of the hazards, doctors must assess medical eligibility requirements (such as age, smoking, history of thrombosis, and migraines with aura) before prescription. Headaches, nausea, and irregular bleeding are typical adverse effects.

Cutting Edge Medical Treatments ^[22][32]

Advanced therapies concentrate on supportive care and hormone regulation:

Progestins (Oral/LNG-IUD): By inhibiting endometrial development, these reduce menstrual bleeding. Although the Levonorgestrel-releasing IUD (LNG-IUD) is quite successful (50%–60% improvement/amenorrhea), women who have fibroids greater than $3\text{ cm}$ are more likely to have their IUD expelled.

Selective Progesterone Receptor Modulators (SPRMs): Drugs such as Ulipristal Acetate (UPA) efficiently reduce bleeding and cause fibroid shrinkage ($25\%–$50\%$ decrease). However, because to worries about liver damage, its supply is limited in some areas (such as the US).

GnRH Agonists: These, such as leuprolide, induce a transient, reversible menopausal state that results in amenorrhea and substantial fibroid reduction ($35\%–$65\%$). They are frequently used to increase hemoglobin levels for three to six months prior to surgery, but concurrent add-back hormone therapy is required due to their side effects (hot flashes, bone loss).

Aromatase Inhibitors (AIs): These, like letrozole, cause a hypoestrogenic condition that improves bleeding and reduces fibroid size by $40\%–$50\%$. More research is required to support their widespread, long-term use, but they are promising and generally better tolerated than GnRH agonists.

Iron Supplementation: Oral and intravenous iron supplementation are essential adjuvant treatments to quickly repair iron deficits and ease related symptoms since severe bleeding frequently results in iron-deficiency anemia.

PROCEDURES IN INTERVENTIONAL RADIOLOGY FOR FIBROIDS^[4][2][34]

For women who want to avoid surgery or are not good candidates for surgery, interventional radiology techniques provide a minimally invasive treatment for fibroids that usually results in a faster recovery.

UAE (Uterine Artery Embolization)

Using injected embolic agents (microspheres), UAE is an angiographic method that stops blood flow to the uterus, killing the fibroids (ischemic necrosis). It reduces fibroids by roughly 42% and alleviates bulk sensations. It treats the entire uterus, which increases the risk of uterine/ovarian damage but provides a quicker recovery than surgery. It has the distinct complication of Post-Embolization Syndrome (pain and fever) and a greater rate of recurrence (20% after five years). It should not be used if you are pregnant, have cancer, or have an ongoing pelvic infection.

MRgFUS/ HIFU, or MR-Guided Focused Ultrasound

MRgFUS is a fibroid-specific treatment that induces coagulative necrosis using high-intensity ultrasound pulses guided by real-time MRI. At six months, over 71% of women say their symptoms have improved. Despite being incisionless, the re-intervention rate is substantial ($30.5\%$). Metal implants (pacemakers), numerous or extremely big fibroids (>$10\text{ cm}$), and significant abdominal scarring are among the contraindications.

CURRENT METHODS OF TREATING UTERINE FIBROIDS SURGICALLY:^[2][5]

Myomectomy (removal of fibroids), Hysterectomy (removal of the uterus as a definitive cure), Uterine Artery Embolization (UAE), and other ablative operations (such as MRgFUS) are examples of current techniques. Retaining the ovaries during a hysterectomy is typically advised for benign illness in premenopausal women under 50, since bilateral oophorectomy is linked to higher mortality.

Myomectomy by hysteroscopy:[16[26]

Function: Common minimally invasive treatment for fibroids that protrude into the uterus (submucosal fibroids, FIGO Types 0–2).

Method: Using a resectoscope or morcellator, fibroids can be removed by cutting/extraction or one-step excision (slicing). Larger fibroids might need to be treated in two steps.

dangers: Perforation and fluid intravasation are among the dangers associated with larger fibroids.

Results: Pooled pregnancy rates are around, indicating favorable reproductive results.

Myomectomy via laparoscopy: [29,30]

Function: With comparable reproductive success (pooled pregnancy rates of to), minimally invasive keyhole surgery offers quicker recovery and less morbidity than open surgery.

Risk: There is a rare chance that fibroids removed by morcellation (cutting into fragments) will spread undetected leiomyosarcoma (prevalence). Although recommended, in-bag morcellation has not been shown to be beneficial.

Contraindications: Extremely large () or many intramural fibroids.

The definitive cure, hysterectomy

Due to its superior access and comparable complication rates to vaginal hysterectomy (VH), laparoscopic hysterectomy (LH) is currently favored over abdominal hysterectomy. It is only available to women who don't want to get pregnant again. The use of morcellation for the removed uterus bears the same risk of occult sarcoma spread, and LH is limited by extremely big uterine volume (weeks' size).[35]

Additional Ablative Methods

Fibroid tissue is destroyed via laparoscopic techniques such as thermo-coagulation (heating) and cryomyolysis (freezing). The primary disadvantage is that there is insufficient tissue for histological evaluation, making it impossible to rule out cancer.[16,4]

PROSPECTS FOR TREATING UTERINE FIBROIDS IN THE FUTURE

Uterine fibroids are a serious global public health concern because they significantly impair women's quality of life during the reproductive years and create significant health concerns.[4][8] There are several medicinal, minimally invasive, and surgical treatments; however, each patient's symptoms, fertility objectives, and general health must be taken into consideration. Even if our knowledge of fibroid biology has advanced, additional study is required to identify their genetic and molecular characteristics, create pharmacological targets that are favorable to fertility, and improve individualized treatment.[22]

Innovative treatments targeting hormone receptors, extracellular matrix, and new chemicals specific to fibroids should be investigated in future research. To create evidence-based recommendations and enhance patient counseling, comparative efficacy studies like COMPARE-UF are crucial. In order to treat fibroids and put preventive measures in place, risk-stratification methods are also required to identify women who are at high risk.[31]

REFLECTION

Because of their high frequency, substantial symptomatology, and effects on fertility and quality of life, uterine fibroids continue to be a severe gynecological health burden. Even though they are benign, their progressive character is influenced by their complicated genetic background, hormonal sensitivity, and excessive extracellular matrix formation. For the best care, early diagnosis by suitable imaging and customized treatment choices are crucial. While conventional treatments like NSAIDs, hormonal medications, and surgical procedures continue to be successful, new minimally invasive methods and molecular-targeted therapeutics have encouraging prospects for enhancing results and lowering recurrence. To improve therapeutic accuracy and guarantee improved clinical and reproductive outcomes for women with fibroids, more study into genetic markers, signaling pathways, and individualized treatment approaches is essential.

REFERENCES

1. Marsh, E. E., Wegienka, G., & Williams, D. R. (2024). Uterine fibroids. JAMA: The Journal of the American Medical Association, 331(17), 1492–1493. https://doi.org/10.1001/jama.2024.0447
2. Epidemiology and management of uterine fibroids Emma Giuliani1, Sawsan As-Sanie2, Erica E. (n.d.). Docslib. Retrieved November 20, 2025, from https://docslib.org/doc/5431047/epidemiology-and-management-of-uterine-fibroids-emma-giuliani1-sawsan-as-sanie2-erica-e
3. McWilliams, M. M., & Chennathukuzhi, V. M. (2017). Recent advances in uterine fibroid etiology. Seminars in Reproductive Medicine, 35(2), 181–189. https://doi.org/10.1055/s-0037-1599090
4. Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update. 2016;22(6):665-686. doi:10.1093/humupd/dmw023
5. Sohn GS, Cho S, Kim YM, et al. Current medical treatment of uterine fibroids. Obstet Gynecol Sci. 2018;61(2):192-201. doi:10.5468/ogs.2018.61.2.192
6. De La Cruz MS, Buchanan EM. Uterine Fibroids: Diagnosis and Treatment. Am Fam Physician. 2017;95(2):100-107.
7. Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124(10):1501-1512. doi:10.1111/1471-0528.14640
8. Afshan Bano, Calvin R Wei, Ayesha Abdul Qadir Memon, Muhammad Osama, Shumaila Shaikh, Qararo Shah, Dua Rabel, & Fahad Jibran Siyal. (2023). A COMPREHENSIVE REVIEW OF UTERINE FIBROIDS: PATHOGENESIS, DIAGNOSIS, TREATMENT, AND FUTURE PERSPECTIVES. Journal of Population Therapeutics and Clinical Pharmacology, 30(18), 1961-1974.
9. {Clinical presentation of fibroids}, journal = {Best Practice & Research Clinical Obstetrics & Gynaecology}, volume = {22},number = {4},pages = {615-626},year = {2008},note = {Uterine Fibroids}, issn = {1521-6934},doi = {https://doi.org/10.1016/j.bpobgyn.2008.01.008}
10. Barjon K, Kahn J, Singh M. Uterine Leiomyomata. [Updated 2025 May 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK546680/
11. Uterine fibroids. (n.d.). Medlineplus.gov. Retrieved November 20, 2025, from https://medlineplus.gov/ency/article/000914.htm
12. Key, A. P. (2016, November 3). Uterine fibroids. WebMD. https://www.webmd.com/women/uterine-fibroids/uterine-fibroids
13. Uterine fibroids. (2023, September 7). Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/9130-uterine-fibroids
14. Uterine fibroids. (n.d.-b). Mayo Clinic. Retrieved November 20, 2025, from https://www.mayoclinic.org/diseases-conditions/uterine-fibroids/symptoms-causes/syc-20354288
15. Munusamy, M. M., Sheelaa, W. G., & Lakshmi, V. P. (2017). Clinical presentation and prevalence of uterine fibroids: a 3-year study in 3-decade rural South Indian women. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 6(12), 5596–5601.
16. de la Cruz, M. D. L., & Buchanan, E. (2017). Uterine fibroids: Diagnosis and treatment. American Family Physician, 95(2), 100–107. https://www.aafp.org/pubs/afp/issues/2017/0115/p100.html
17. Qiwei Yang, Michal Ciebiera, Maria Victoria Bariani, Mohamed Ali, Hoda Elkafas, Thomas G Boyer, Ayman Al-Hendy, Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment, Endocrine Reviews, Volume 43, Issue 4, August 2022, Pages 678–719,
18. Stewart EA. Clinical practice. Uterine fibroids. N Engl J Med. 2015;372(17):1646-1655. doi:10.1056/NEJMcp1411029
19. Bulun SE. Uterine fibroids. N Engl J Med. 2013;369(14):1344-1355. doi:10.1056/NEJMra1209993
20. Marsh EE, Ekpo GE, Cardozo ER, Brocks M, Dune T, Cohen LS. Racial differences in fibroid prevalence and ultrasound findings in asymptomatic young women (18-30 years old): a pilot study. Fertil Steril. 2013;99(7):1951-1957. doi:10.1016/j.fertnstert.2013.02.017
21. Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124(10):1501-1512. doi:10.1111/1471-0528.14640
22. Moravek MB, Yin P, Ono M, et al. Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications. Hum Reprod Update. 2015;21(1):1-12. doi:10.1093/humupd/dmu048
23. Hartmann KE, Fonnesbeck C, Surawicz T, et al. Management of Uterine Fibroids [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017 Dec. (Comparative Effectiveness Review, No. 195.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK537742/
24. Marsh EE, Chibber S, Saad W. Patient-Centered Care and Uterine Fibroids. Semin Reprod Med. 2017;35(6):560-564. doi:10.1055/s-0037-1607267
25. @article{Giuliani2020EpidemiologyAM, title={Epidemiology and management of uterine fibroids}, author={Emma Giuliani and Sawsan As-Sanie and Erica E. Marsh}, journal={International Journal of Gynecology \& Obstetrics}, year={2020}, volume={149}, url={https://api.semanticscholar.org/CorpusID:210842764}
26. Aarts JW, Nieboer TE, Johnson N, et al. Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Database Syst Rev. 2015;2015(8):CD003677. Published 2015 Aug 12. doi:10.1002/14651858.CD003677.pub5
27. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science. 2005;308(5728):1589-1592. doi:10.1126/science.1112063
28. Catherino W, Salama A, Potlog-Nahari C, Leppert P, Tsibris J, Segars J. Gene expression studies in leiomyomata: new directions for research. Semin Reprod Med. 2004;22(2):83-90. doi:10.1055/s-2004-828614
29. Alessandri F, Lijoi D, Mistrangelo E, Ferrero S, Ragni N. Randomized study of laparoscopic versus minilaparotomic myomectomy for uterine myomas. J Minim Invasive Gynecol. 2006;13(2):92-97. doi:10.1016/j.jmig.2005.11.008
30. American College of Obstetricians and Gynecologists. ACOG practice bulletin. Alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol. 2008;112(2 Pt 1):387–400.
31. Segars JH, Parrott EC, Nagel JD, et al. Proceedings from the third national institutes of health international congress on advances in uterine leiomyoma research: Comprehensive review, conference summary and future recommendations. Hum Reprod Update. 2014;20:309–333.
32. Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010;116(4):865-875. doi:10.1097/AOG.0b013e3181f20177
33. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100-107. doi:10.1067/mob.2003.99
34. Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol. 2004;104(2):393-406. doi:10.1097/01.AOG.0000136079.62513.39
35. Vilos GA, Allaire C, Laberge PY, Leyland N; SPECIAL CONTRIBUTORS. The management of uterine leiomyomas. J Obstet Gynaecol Can. 2015;37(2):157-178. doi:10.1016/S1701-2163(15)30338-8.